Home > Pulmonology > ERS 2019 > Interstitial Lung Disease > Antifibrotic therapy slows disease progression in ILD

Antifibrotic therapy slows disease progression in ILD

Principal Investigator
Prof. Luca Richeldi, University of Southampton, United Kingdom
ERS 2019
Results from the INBUILD trial show that nintedanib slowed lung function decline in patients with interstitial lung disease (ILD) other than idiopathic pulmonary fibrosis (IPF) by 57% across the overall study population over 52 weeks [1]. Up to now, there are no treatment options for patients with non-IPF. The tyrosine kinase inhibitor nintedanib is currently approved for the treatment of IPF as a result of the INPULSIS trials [2,3]. Some patients with ILDs other than IPF also develop a progressive fibrosing phenotype, characterised by an increasing extent of fibrosis on high-resolution computed tomography (HRCT), decline in lung function, worsening symptoms, and early mortality [4]. Prof. Luca Richeldi (University of Southampton, United Kingdom) pointed out that preclinical studies have shown that nintedanib inhibits processes involved in the progression of fibrosis, irrespective of the trigger [5]. This suggests that nintedanib may also reduce the progre...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on